6 news items
Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical Officer
RGLS
16 May 24
President, Regulatory Affairs and Safety, at Sanifit Therapeutics. Prior to that, she was Vice President at Infinity Pharmaceuticals and served in multiple
Regulus Therapeutics Advances To Cohort 4 Of Phase 1b Multiple-Ascending Dose Clinical Trial Of RGLS8429 For The Treatment Of Autosomal Dominant Polycystic Kidney Disease
RGLS
6 May 24
available safety data, the Company initiated screening in the of the fourth cohort of patients in the Phase 1b MAD study of RGSL8429 for the treatment
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RGLS
6 May 24
(the "Company" or "Regulus"), today announced, after review of all available safety data, the Company initiated screening in the of the fourth
Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Updates
RGLS
21 Mar 24
or placebo every other week for three months. RGLS8429 was well tolerated with no safety findings of concern. Greater biological activity of RGLS8429
Why Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday?
RGLS
12 Mar 24
was well tolerated, with no safety findings of concern.
Clear evidence of a mechanistic dose response at a 2mg/kg dose level based on urinary
4yjycsu dl15bgkttf
RGLS
12 Mar 24
evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics (PK/PD) of RGLS8429 in adult patients with ADPKD. The study is evaluating
- Prev
- 1
- Next